InvestorsHub Logo
Followers 840
Posts 120462
Boards Moderated 18
Alias Born 09/05/2002

Re: scott2987 post# 468

Monday, 07/11/2016 4:26:02 PM

Monday, July 11, 2016 4:26:02 PM

Post# of 592
Angiomax is protected by two Orange Book patents that run until Jan 2029, which (given today’s CAFC ruling) will keep generic versions of Angiomax off the US market for a long time:

http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020873&Product_No=001&table1=OB_Rx

So, yes—this is a lucrative market opportunity for EGRX.

(Note: Kangio does not infringe MDCO’s patents, and EGRX has not been sued by MDCO with respect to Kangio.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EGRX News